Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers

Not Applicable

Recruiting

• Conditions: Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Peritoneal Neoplasms
• Interventions: Other: Biological collection

• Registration Number: NCT03976999
• Lead Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle

Brief Summary

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to epithetial ovarian cancer, Fallopian tube cancer and Primitive peritoneal cancer.

Detailed Description

A Clinical and Biological Database is a collection of reliable, prospective and representative datas.

This collection, provided to the scientific community, will help to develope research programs such as :

* Cinicals and biological predictive factors of treatments response

* Identification of biological tumoral markers associate with survival

* Identification of prognosic factors after recidivism

* Diagnostics tests optimisation and follow-up from blood samples ( Circulating Tumor Cells (CTC) )

* Developing strong preclinical models. Those models would be later used to test alternative treatments and would help to identify new biomarkers

Study Timeline

• Study Start: 2017-07-05
• Study First Submitted: 2019-06-05
• Study First Submitted QC: 2019-06-05
• Study First Posted: 2019-06-06
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-12
• Primary Completion: 2027-07
• Study Completion: 2032-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• 18 or older
• Patient at the diagnosis of an epithelial ovarian cancer, or a fallopian tube caner or a primitive peritoneal cancer
• Patient eligible for, at least, one surgery and a chemotherapy
• Patient having given his informed, written and express consent

Exclusion Criteria

• Patient not affiliated to a social protection scheme
• Pregnant and / or nursing women
• Subject under tutelage, curatorship or safeguard of justice
• Patient whose regular follow-up is impossible for psychological, familial, social or geographical reasons

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Biological collection	Biological collection	For all the patients include in the studie : * Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4) * Tissue samples (tumor tissue and healthy tissue) collected during the surgery In parallel to this biological collection, standardized clinical data will be entered into a database

Primary Outcome Measures

Name	Time	Method
Proportion of patients who gave their consent to participate in the study	Until the study completion : 3 years	The proportion of patients who consent to participate in the study among the screened patients

Trial Locations

Locations (1)

ICM - Institut régional du Cancer Montpellier; 🇫🇷 Montpellier, France